| 7.87 -0.07 (-0.88%) | 03-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
ChromaDex Corporation is a bioscience enterprise committed to advancing healthy aging. The company's operations are segmented into three primary areas: Consumer Products, Ingredients, and Analytical Reference Standards and Services. Its research efforts largely concentrate on nicotinamide adenine dinucleotide (NAD+). Under its Consumer Products division, ChromaDex provides finished dietary supplements, which incorporate its proprietary ingredients, directly to consumers and through distributors. A flagship offering is TRU NIAGEN, a supplement featuring NIAGEN, the company's proprietary nicotinamide riboside (an NAD+ precursor) as its active component. The Ingredients segment is responsible for the development and commercialization of specialized ingredient technologies. It supplies these unique raw materials, including NIAGEN, to other manufacturers for use in their consumer products. Another significant ingredient is IMMULINA, composed of Braun-type lipoproteins and spirulina extracts, which is designed to support immune system function. Additionally, ChromaDex offers analytical reference standards and services. These products are vital for performing quality control checks on raw materials and finished goods within industries such as dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceuticals. TRU NIAGEN products reach consumers via multiple channels, including ChromaDex's dedicated e-commerce site, TRUNIAGEN.com, as well as Amazon and other online marketplaces. Distribution also extends to specialty retailers and directly to healthcare practitioners within the United States. ChromaDex Corporation's main office is located in Los Angeles, California.
Thu, 27 Aug 2026
Chromadex Corp (CDXC) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Thu, 24 Apr 2025
ChromaDex Corporation (CDXC) Stock Price, News & Analysis - Stock Titan
Thu, 13 Mar 2025
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Business Wire
Fri, 20 Sep 2024
ChromaDex Appoints Ozan Pamir as Chief Financial Officer - BioSpace
Thu, 25 Apr 2024
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|